Mengyang Pharmaceutical Co., Ltd. was founded in February 2009, located in Jingmen City, Hubei Province, covering an area of 100 mu, now has more than 200 employees, is a joint-stock modern pharmaceutical high-tech enterprise integrating research and development, production and marketing, mainly engaged in the research and development, production and sales of natural drugs, health food. The company adheres to the values of "patient-centered, unmet clinical needs as guidance, integrity, innovation and continuous struggle", takes "improving the quality of life of cancer patients" as its mission, and is committed to becoming "a leader in the field of cancer treatment related diseases".

Main products of the company: "Shengbai Oral Liquid (mixture)" was developed by Professor Shao Mengyang, a famous doctor of traditional Chinese medicine, with lifelong efforts. It has independent intellectual property rights, won a Chinese patent for invention, and won a number of domestic and international awards. As a treatment drug for leukopenia caused by tumor radiotherapy and chemotherapy and a drug to improve immunity, the product has brought health and hope to countless patients. "Polyporus Capsule" is a new drug discovered by Professor Zhang Ronglie, a senior researcher of China Academy of Chinese Medical Sciences, and led a team of scientists to develop successfully. Polyporus has long carried out in-depth research in China and Japan, and its liver protection and enhancement of immune function in the clinical treatment of chronic viral hepatitis B and tumor has obtained a good effect. "Huangqi Beishachan Granules" and "Rhodiola Astragalus Granules" are two health foods carefully developed by Professor Lin Hongsheng, chief researcher of China Academy of Chinese Medical Sciences and president of the International TCM Tumor Alliance. They are used for physical recuperation of cancer patients in the rehabilitation stage, and practice the theory of "strengthening the root and eliminating the source, five treatments and five nourishs".

Mengyang Pharmaceutical (Shanghai) Co., Ltd. It is a wholly-owned subsidiary of Hubei Mengyang Pharmaceutical Co., LTD., and an innovative drug research and development and production base. Mainly engaged in the research and development, production and sales of high-end preparations and biological preparations, and the introduction and development of innovative drugs. At present, there are three new small-molecule drugs of class I in development, among which DH001 (which can reduce the incidence and severity of cardiotoxicity caused by adriamycin and is suitable for patients receiving adriamycin treatment) has been approved for clinical study and has entered phase II clinical study, and MY0063 is suitable for thrombocytopenia caused by radiotherapy and chemotherapy in tumor patients. MY00 is suitable for acute radiation sickness, and the last two drugs are still in the process of development.

Mengyang Pharmaceutical is committed to excavating the treasure of traditional Chinese medicine, developing the classic prescriptions of famous old Chinese medicine and the effective ingredients from natural medicines into new drugs, protecting the intangible cultural heritage of China and benefiting mankind. The company adheres to the principle of serving the country with industry and continuous innovation. In today's increasingly powerful motherland and when the Chinese people are striving to realize the Chinese dream of the great rejuvenation of the Chinese nation, Mengyang Pharmaceutical, as a responsible national pharmaceutical enterprise, will do its best to realize the dream of promoting the medicine of the motherland and bringing health to patients!